Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

  • Carew J
  • Giles F
  • Nawrocki S
  • 80

    Readers

    Mendeley users who have this article in their library.
  • 312

    Citations

    Citations of this article.

Abstract

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs are a promising target for pharmacological inhibition. HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death. These properties have prompted numerous preclinical and clinical investigations evaluating the potential efficacy of HDAC inhibitors for a variety of malignancies. The preferential toxicity of HDAC inhibitors in transformed cells and their ability to synergistically enhance the anticancer activity of many chemotherapeutic agents has further generated interest in this novel class of drugs. Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents. © 2008 Elsevier Ireland Ltd. All rights reserved.

Author-supplied keywords

  • Apoptosis
  • Autophagy
  • Bortezomib
  • Histone deacetylase inhibitor
  • TRAIL

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Jennifer S. Carew

  • Francis J. Giles

  • Steffan T. Nawrocki

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free